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Abstract 
Breast cancer risk increases transiently in the period following pregnancy; pregnancy‑associated breast cancers 
(PABC) are more aggressive than cases diagnosed in nulliparous women. We have previously reported that in the 
normal human breast pregnancy results in the upregulation of a number of inflammation related genes, suggesting 
a pro‑tumorigenic environment as well as downregulation of ESR1 (ERα) and ERBB2 (HER2) and upregulation of ESR2 
(ERβ), suggesting a protective effect. In this study, we aimed to investigate the possibility of differential regulation of 
the same gene set modulated in the normal breast, in human breast tumors following pregnancy. Gene expression 
was measured by real‑time PCR on tumor regions isolated by laser capture microdissection from paraffin sections. 
Immunohistochemistry was performed on tissue microarrays (TMA) for protein expression. Hierarchical clustering 
was performed using the average linkage method to determine coordinate expression of sets of genes. We find that 
breast cancers detected within 10 years following pregnancy display a different gene expression pattern than those 
detected in nulliparous breast cancer patients. The gene expression difference is mainly attributable to a triple nega‑
tive (TNBC) subgroup found to be more frequent in PABCs up to 10 years following a pregnancy. We also show that 
protein and mRNA expression levels correlate in half of the proteins tested by TMA. Despite the fact that this is a small 
study of 53 patients, we identified a gene expression signature that is differentially expressed in pregnancy‑associated 
TNBC.
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Background
Epidemiological studies have long established a link 
between breast cancer risk and a completed pregnancy. 
Pregnancy, especially if it occurs at an early age, is gen-
erally considered to be protective against breast cancer. 
However, rigorous epidemiological studies have shown 
that the protection conferred by pregnancy is delayed 
and that the period following completion of pregnancy/
lactation is characterized by an increase in breast cancer 
risk (Schedin 2006; Albrektsen et  al. 2005; Lambe et  al. 
1994). This risk period encompasses at least 7–10 years, 
and varies according to, among other factors, the age 
of the mother at first pregnancy, with older first time 
mothers showing the longest increased risk period. 
Pregnancy-associated breast cancers (PABCs) diagnosed 
within this period tend to be aggressive, with high mor-
tality rates (Bladstrom et al. 2003; Johansson et al. 2011). 
In women diagnosed with breast cancer within 1 year of 
giving birth, the 15 year survival rate is only half that of 
age matched nulliparous women (Whiteman et al. 2004).
One hypothesis, supported by animal model data, 
asserts that the process of breast involution following 
pregnancy is tumor-promoting and/or tumorigenic, due 
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to the profound remodeling that occurs in the mammary 
gland during this time (Schedin 2006; Lyons et al. 2011; 
Clarkson et  al. 2004). These changes include extracellu-
lar matrix (ECM) remodeling, angiogenesis and inflam-
matory processes that share characteristics with wound 
healing programs as evidenced by animal studies of 
forced weaning (Stein et al. 2004).
By utilizing a gene set containing 64 genes involved 
in inflammation, ECM remodeling, angiogenesis and a 
number of breast cancer biomarkers, we have previously 
reported that the normal human breast environment 
following pregnancy is associated with upregulation of 
a number of inflammation related genes (Asztalos et  al. 
2010), supporting the hypothesis for the role of involu-
tion in PABC. At the same time we found evidence for a 
protective effect, as shown by repression of ESR1 (ERα) 
and ERBB2 (HER2-neu) and increased expression of 
ESR2 (ERβ). In the present study we investigated the pos-
sibility of differential regulation of the same set of genes 
in human breast tumors from nulliparous and parous 
patients. We find that breast tumors detected follow-
ing a pregnancy show a different gene expression pat-
tern than those detected in nulliparous women. The gene 
expression difference is mainly attributable to a triple 
negative breast cancer (TNBC) subgroup that was more 
prevalent in PABCs than in the nulliparous group. This 
parous TNBC subgroup was characterized by differential 
expression of 14 out of the 64 genes, compared to nullip-
arous subjects and parous non-TNBC subjects, assayed 
in the study. While our findings independently confirm 
other studies that report a higher incidence of TNBC 
diagnosed in PABCs compared to nulliparous patients 
(Pilewskie et al. 2012; Madaras et al. 2014), this study is 
the first to report the prevalence of TNBC in patients 




Patients between 18 to 45  years of age who were diag-
nosed with breast cancer, selected from the University 
of Illinois at Chicago Hospital, Northwestern Memorial 
Hospital (Chicago) and Abbott Northwestern Hospital 
(Minneapolis). The Institutional Review Boards of each 
institution approved this study (Protocol #2006-0889). 
Patients were eligible for study if their paraffin blocks 
were available and parity status and time interval since 
their last pregnancy was known. Patients were divided 
into categories according to the time elapsed since their 
last pregnancy at the time of tumor tissue collection as 
follows: nulliparous, recent pregnancy (0–2  years since 
last pregnancy) and more distant pregnancy (5–10 years 
since pregnancy). The clinical characteristics of the 
tumors and patients are summarized in Table 1.
Laser capture microdissection, RNA isolation, cDNA 
synthesis, linear amplification
Laser capture microdissection of tumor regions from 
paraffin sections was done as previously described (Asz-
talos et al. 2010). RNA was extracted from 19 nulliparous, 
17 recent pregnancy and 17 distant pregnancy samples. 
RNA isolation, cDNA synthesis and pre-amplification 
was done as previously described (Asztalos et al. 2010).
Real time PCR
We selected 64 genes involved in the processes of inflam-
mation, ECM remodeling or angiogenesis, as previously 
described (Asztalos et  al. 2010). Gene expression was 
measured using customized Taqman® assays that ampli-
fied short amplicons. For each sample, Ct values of each 
gene of interest were normalized to the average Ct val-
ues of housekeeping genes ACTB and HPRT1 (delta Ct). 
Delta Ct values (or housekeeping-gene adjusted gene 
expression) were used for statistical analysis for differ-
ences among groups (Additional file  1). For the ease of 
presenting these differences, delta Ct values were anti-
logged and expressed as fold-changes relative to a refer-
ence group within the study population.
Table 1 Sample characteristics
Unless otherwise stated, numbers indicate patients in each category with 





Sample size 19 17 17
Tumor size (cm) 
(mean ± SD)
2.7 ± 1.7 2.0 ± 1.2 4.6 ± 4.5
Age at diagnosis 
(mean ± SD)
36 ± 5 38 ± 3 36 ± 7
Pregnancies 
(mean ± SD)
0 2.0 ± 1.0 1.9 ± 0.7
Tumor grade
 I 2 (11 %) 0 (0 %) 2 (12 %)
 II 12 (63 %) 2 (12 %) 4 (24 %)
 III 4 (21 %) 13 (76 %) 10 (59 %)
 NA 1 (5 %) 2 (12 %) 1 (6 %)
ERα+ 16 (84 %) 9 (53 %) 7 (41 %)
PR+ 10 (53 %) 9 (53 %) 6 (35 %)
Her2/neu+ 8 (42 %) 6 (35 %) 5 (29 %)
Triple negative 
status
 TNBCs 1 (5 %) 7 (41 %) 7 (41 %)
 Non‑TNBCs 18 (95 %) 10 (59 %) 10 (59 %)
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Immunohistochemistry (IHC)
TMA blocks were sectioned to 4  µm thickness. IHC 
for ERα, PR and HER2 was performed at the University 
of Illinois at Chicago Medical Center following stand-
ard protocols with a Ventana Benchmark® system. For 
all other proteins, following deparaffinization/rehydra-
tion, samples were incubated in sodium citrate antigen 
retrieval buffer pH 6.0 at 95  °C for 20  min and allowed 
to cool to room temperature. IHC was then performed 
using the Dako Envision Plus® system. Antibodies, incu-
bation times and dilutions used can be found in Addi-
tional file 2. Slides were counterstained with hematoxylin 
and permanently mounted.
Tissue microarrays (TMAs) and image analysis
TMAs were constructed using 2 mm diameter cores. For 
each patient, triplicate cores were placed adjacent to each 
other on the TMA; samples belonging to the three preg-
nancy categories were placed at random to avoid posi-
tional effects. After staining, samples were scanned at 
200× using an Aperio ScanScope CS® (Leica Biosystems, 
Inc., Vista, CA) digital microscopy system. Tumor regions 
were outlined using the software draw tool. The various 
stains were analyzed by automated Aperio algorithms, 
according to their predominant pattern of localization 
within cells. ERα and PR were scored by a nuclear algo-
rithm; HER2 and CDH1 by a membrane algorithm; and 
CXCL1, TGFB3 by an algorithm for cytoplasmic staining. 
Calculations for nuclear and membrane algorithm can be 
found in Additional file 3. ER, PR and HER2 clinical sta-
tus was provided by each hospital and was independently 
verified by co-investigator pathologists (RE, EW) and by 
digital image analysis. In cases of disagreement between 
pathologist and digital analysis score, the pathologist 
score was used; however, there was excellent correlation 
between the two scoring methods (p < .001).
Statistical analysis
Expression of individual genes was compared between 
groups with either a two-sided t test, when two groups 
were compared, or a one-way ANOVA, followed by 
Tukey’s HSD test, when more than two groups were 
compared. Unsupervised hierarchical clustering was 
performed using the average linkage method to deter-
mine coordinate expression of sets of genes (Cluster soft-
ware) (Eisen et al. 1998), and results were visualized with 
Treeview (Eisen et  al. 1998). To analyze distribution of 
TNBC samples between nulliparous and parous groups, 
Fisher’s exact test was used.
For TMA data analysis, triplicate spots (where avail-
able—some spots were excluded due to missing tissue) 
were averaged. Statistical analysis of normally distributed 
data consisted of one-way ANOVA, followed by Tukey’s 
HSD test for three groups or a two-sided t test for two 
groups. For non-normally distributed data, Wilcoxon’s 
exact test was used.
Results
Prevalence of high grade, triple negative subtype in parous 
samples
Our patient population was closely matched for age at 
diagnosis and average tumor size (Table  1). We noticed 
that the two parous groups displayed more tumors of 
higher grade compared to the nulliparous group. Indeed, 
there is a significant difference in terms of grade distribu-
tion when the nulliparous group was compared to recent 
pregnancy (p < 0.001), distant pregnancy (p < 0.05), and 
the combined parous group (p < 0.001) respectively. We 
also found that this combined parous group presented a 
higher percentage of TNBC cases compared to the nul-
liparous group (Fisher’s exact test, p  <  0.01). The inci-
dence of HER2-expressing cases observed in all groups 
is higher than for an unselected breast cancer population 
(~20 %), which reflects the limitation of our small sample 
size.
Identification of genes differentially expressed 
between tumors of nulliparous and parous women
Since it is reported that breast cancers occurring at vari-
ous time intervals following pregnancy differ in terms of 
their outcomes (Schedin 2006), we initially distinguished 
between a recent pregnancy and distant pregnancy 
group. However, since we found that no genes were dif-
ferentially expressed between the recent (<2  years) and 
distant parity (5–10  years) groups (Table  2), we com-
bined them into a single parous group for subsequent 
Table 2 Genes showing differential expression 
between  nulliparous and  parous tumors as  determined 
by real time PCR
Gene expression averages were normalized to the nulliparous group. Mean ± SE 
are shown. Parous includes recent and distant pregnancies. p value is for t 
test comparing nulliparous to parous. N nulliparous tumors = 19, N recent 
pregnancy tumors = 17, N distant pregnancy tumors = 17, N parous (combined 






CXCL1 1 ± 0.2 4.6 ± 1.1 4.7 ± 1.5 4.4 ± 1.6 0.005
THBS1 1 ± 0.2 0.5 ± 0.0 0.5 ± 0.1 0.5 ± 0.0 0.01
ESR1 1 ± 0.2 0.3 ± 0.0 0.2 ± 0.0 0.3 ± 0.1 0.01
ELN 1 ± 0.2 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.1 0.018
TGFB3 1 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.6 ± 0.1 0.022
ADAM9 1 ± 0.1 0.6 ± 0.0 0.6 ± 0.0 0.6 ± 0.0 0.025
IL11 1 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.1 0.026
CDH1 1 ± 0.1 0.5 ± 0.0 0.6 ± 0.0 0.5 ± 0.0 0.037
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analyses. Eight genes are differentially expressed in breast 
cancer tissues when the parous and nulliparous subjects 
are compared, as summarized in Table 2.
We performed an unsupervised clustering analysis to 
determine the ability of this eight-gene set to differentiate 
nulliparous and parous tumors. The hierarchical cluster-
ing tree is shown in Fig. 1. Based on the first bifurcation, 
one cluster is predominantly composed of parous sub-
jects and the other of nulliparous subjects; 56 % of parous 
subjects were included in the “parous” cluster, versus only 
21 % of the nulliparous subjects (Fisher’s exact, p = 0.02). 
Correspondingly, 79  % of the nulliparous patients and 
44  % of the parous patients were included in the “nul-
liparous cluster”. This suggests that the nulliparous group 
was somewhat more homogenous in terms of the expres-
sion of these eight genes than the parous group.
Prevalence of TNBC by parity group and a triple negative 
gene set
Given the high frequency of TNBCs in the parous groups 
compared to the nulliparous as mentioned above, we 
were interested in determining whether this group is 
characterized by a different gene expression profile. 
We therefore separated our samples into three groups: 
parous TNBC, parous non-TNBC, and nulliparous 
non-TNBC. The nulliparous TNBC samples were not 
included as a group since we only had one sample in that 
category. Of the 64 total genes, 14 genes characterized 
the parous TNBCs (Table 3). These 14 genes included 5 
of the 8 genes found to be associated with parous breast 
cancers (CXCL1, THBS1, ESR1, ELN, TGFB3) (Table 2), 
which were found to be down-regulated in the parous 
TNBC group compared to the other two. This suggests 
that the differences originally identified between the 
nulliparous and parous cancer groups were potentially 
due to the parous TNBC subgroup. It is worthwhile to 
note that none of these 14 genes was found to be different 
between the non-TNBC parous and non-TNBC nullipa-
rous groups.
To determine how these 14 genes (Table 3) can differ-
entiate between TNBCs and non-TNBCs, average linkage 
clustering was performed. Judged by the first bifurca-
tion, the clustering power of the gene set was very effi-
cient, with only four of 38 non-TNBC samples and none 
of 15 TNBC samples misclassified (Fig.  2a). Since three 
of these 14 genes (ESR1, PGR, and ERBB2) themselves 
identify the TNBC subtype, we repeated average linkage 
clustering with the other 11 genes and examined their 
efficiency at differentiating TNBC from non-TNBC. We 
observed that even without these three biomarkers, the 
gene set was able to correctly classify 11 out of 15 TNBC 
cases (Fig. 2b).
IHC and correlation between mRNA and protein levels 
for selected genes
Given that mRNA and protein levels do not necessar-
ily correlate, we were interested in the identification of 
possible protein level differences between the parous 
and nulliparous cancers. TMAs were constructed and 
IHC was performed for six proteins. These proteins 
were chosen because they were part of either the 8- or 
14-gene set set identified in Tables  2 and 3 (ERα, PR, 
HER2, CDH1, CXCL1, TGFB3). Since no differences 
in protein expression were detected between the two 
parous categories, they were again pooled into one 
parous group and compared to the nulliparous cat-
egory. We observed a statistically significant correla-
tion between mRNA and protein level for ERα, PR and 
Fig. 1 Clustering of tumor samples based on the genes significantly differently expressed between the nulliparous (NP) and parous (P) tumor 
samples. N NP = 19, N P = 34
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HER2, with correlation coefficients of 0.71, 0.70, and 
0.79 (all p < 0.0001) respectively. CDH1 mRNA and pro-
tein expression were also statistically correlated, albeit 
less strongly (correlation coefficient 0.4, p =  0.01). We 
found no correlation between mRNA and protein level 
for CXCL1 and TGFB3 Additional file 4.
Discussion
It is now recognized that the post pregnancy period is 
associated with an increased breast cancer incidence and 
more aggressive breast cancers (Schedin 2006; Ali et  al. 
2012; Lyons et  al. 2009). It is hypothesized that a vari-
ety of factors are responsible for these findings, includ-
ing the hormonal milieu, immune suppression during 
pregnancy, as well as difficulties in detection of cancers 
following birth due to increased breast density (Schedin 
2006; Lyons et  al. 2009). Involution, the natural physi-
ological process by which the breast returns to its pre-
pregnant state, has been hypothesized to be one of the 
factors contributing to the incidence and aggressiveness 
of PABCs (Schedin 2006; O’Brien and Schedin 2009; Jin-
dal et al. 2014). Involution shares characteristics with an 
inflammatory environment (Stein et  al. 2004), which in 
turn is supportive of tumor growth and spread (Lyons 
et al. 2011). We previously reported a specific gene signa-
ture that is able to discriminate between nulliparous and 
parous normal breast, suggesting that parity increases 
inflammatory processes and at the same time imparts 
protective effects such as alterations in estrogen respon-
siveness that could be more durable (Asztalos et al. 2010). 
Here, we investigated the possibility of such genes play-
ing a role in PABCs. We first noticed that tumors from 
the parous group, regardless of time lapse between preg-
nancy and diagnosis, presented with a higher grade com-
pared to the tumors from the nulliparous group. This 
observation has been attributed to a diagnostic delay 
between occurrence of the presenting symptoms and the 
initiation of breast mass workup (Basaran et al. 2014). In 
fact, there have been several reports on an association 
between PABC and high grade tumors (Basaran et  al. 
2014; Langer et al. 2014; Murphy et al. 2012). However, 
all of these studies were conducted using tumors from 
patients whose cancer was diagnosed either during preg-
nancy or within 1 year of delivery. Our study is the first to 
show that this high grade feature remains associated with 
PABC up to 10 years after pregnancy, and is therefore less 
likely to be due to decreased ascertainment associated 
with the post-partum period.
Gene expression profiling of our samples revealed 
that the two parous subsets were homogenous in terms 
of their expression profile and were different from the 
nulliparous group as defined by the expression of eight 
genes (Table 2). This suggests that pregnancy-associated 
changes persist in the human breast tumors for as long 
as 5–10  years after delivery. When this eight-gene set 
was used to discriminate between nulliparous and parous 
Table 3 Genes differentially expressed between parous TNBCs, parous non-TNBCs and nulliparous non-TNBCs
Statistical analysis was done using delta Ct values or housekeeping-gene adjusted gene expression (see Additional file 1). For the ease of presenting these differences, 
delta Ct values were anti-logged and expressed as fold-changes relative to parous TNBC group (A) as seen in the table below. All genes were significantly differently 
expressed in the parous TNBC group compared to the other two groups based on ANOVA followed by Tukey’s HSD test. The values for the parous (B) and nulliparous 
non-TNBCs (C) were not significantly different from each other. TNBC nulliparous group was not included since it contains only one sample. CT values were normalized 
to parous TNBC group (A). Averages ± SE shown
ns not significant
For Tukey’s HSD test * p < 0.05; ** p < 0.01; *** p < 0.001 significant levels
Parous TNBCs (A) Parous non-TNBCs (B) Nulliparous non-TNBCs (C) A versus B A versus C B versus C
CXCL1 1.0 ± 0.3 0.3 ± 0.1 0.1 ± 0.0 * *** ns
CXCL12 1.0 ± 0.2 3.4 ± 0.5 2.3 ± 0.3 *** * ns
ELN 1.0 ± 0.4 2.2 ± 0.4 3.3 ± 0.7 ** ** ns
ERBB2 1.0 ± 0.1 25.8 ± 8.4 5.6 ± 1.1 *** *** ns
ESR1 1.0 ± 0.3 23.7 ± 5.1 49.9 ± 14.4 *** *** ns
FBN1 1.0 ± 0.3 2.1 ± 0.3 2.5 ± 0.5 ** ** ns
IL1A 1.0 ± 0.7 0.1 ± 0.0 0.1 ± 0.0 * ** ns
IL8 1.0 ± 0.3 0.4 ± 0.1 0.4 ± 0.2 ** ** ns
MMP12 1.0 ± 0.5 0.2 ± 0.1 0.4 ± 0.2 * * ns
MMP2 1.0 ± 0.3 1.9 ± 0.3 2.0 ± 0.4 * * ns
PGR 1.0 ± 0.3 154.1 ± 75.4 162.8 ± 57.0 *** *** ns
TGFB3 1.0 ± 0.2 3.3 ± 0.4 4.2 ± 0.7 *** *** ns
THBS1 1.0 ± 0.3 1.8 ± 0.2 2.6 ± 0.6 *** *** ns
TIMP2 1.0 ± 0.3 2.1 ± 0.3 2.0 ± 0.3 *** ** ns
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tumors, we found that the nulliparous group was more 
homogenous in terms of their gene expression compared 
to their parous counterpart.
Another interesting finding of our study was that 
TNBCs occur more frequently in PABCs than in nullipa-
rous cancers. In fact we only had one TNBC sample in 
the nulliparous group, which prevented us from includ-
ing a nulliparous TNBC subgroup for gene comparison 
purposes. We found that the parous TNBC group differ-
entially expressed a subset of 14 genes, five of which also 
showed differential expression between the parous cases 
and their nulliparous counterpart. Therefore we conclude 
that the major factor in gene expression differences asso-
ciated with pregnancy is attributable to the TNBC sub-
group of the PABCs. Most interesting is the finding that 
five of these genes (TGFB3, ESR1, PGR, TIMP2, ERBB2) 
Fig. 2 Clustering of tumor samples based on the gene set of a 14 genes including ESR1, PGR, and ERBB2, and b 11 genes excluding ESR1, PGR, 
and ERBB2. Samples labeled with 1 are TNBCs, samples labeled with 0 are non‑TNBCs. NP nulliparous, PP parous, N TN parous = 14, N non‑TN 
parous = 20, N TN nulliparous = 1, N non‑TN nulliparous = 18
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are common to the gene set that distinguishes the normal 
parous breast from the normal nulliparous breast and six 
of these genes (CXCL1, CXCL12, ERBB2, IL1A, MMP12, 
TIMP2) are common to the inflammatory signature we 
previously reported (Asztalos et  al. 2010). The expres-
sion of five genes (TGFB3, ESR1, PGR, TIMP2, ERBB2) 
is in the same direction in the parous normal breast and 
the pregnancy-associated TNBC with the exception of 
TIMP2. Three of these genes, ESR1, PGR and ERBB2, are 
associated with the protective effects of pregnancy in the 
normal breast whereas lack of expression of these genes 
defines the TNBC subtype. Nonetheless, the consistency 
of expression of a subset of genes found in both the nor-
mal parous breast and in parous TNBCs is a significant 
finding that may have implications for potential biomark-
ers of breast cancer risk. These data are consistent with 
the hypothesis that pregnancy creates a tissue microenvi-
ronment favorable for the development of TNBCs.
Our finding that PABCs show a higher incidence of 
the TNBC phenotype than the cancers of nulliparous 
women are in agreement with Pilewskie et al. (2012) who 
report that TNBCs are statistically more likely to occur in 
recent pregnancy associated (within 2 years) breast can-
cers than all other categories. In that study, TNBCs com-
prised 34  % of the total in the recent pregnancy group 
(0–2 years) compared to 11 % in the nulliparous group. 
Another recent study examined the frequency of TNBC 
in patients that included 31 patients diagnosed during 
pregnancy or within 1  year of delivery (Madaras et  al. 
2014) and also observed a higher frequency of TNBC 
compared to the nulliparous group. Our findings closely 
mirror those results, with TNBCs comprising 41  % in 
both pregnancy groups and only 5  % in the nulliparous 
group. To that end, this study presents new data that 
indicate TNBC risk can persist beyond 2 years after preg-
nancy. These findings are particularly important since the 
TNBC phenotype is associated with poor prognosis in 
numerous studies (Carey et al. 2006; Liedtke et al. 2008; 
Cheang et al. 2008; Nguyen et al. 2008; Tan et al. 2008). 
The relatively high frequency of TNBCs could contribute 
to the overall bad prognosis that characterizes tumors 
detected after pregnancy.
It is recognized that various molecular subtypes of 
breast cancers exist, characterized by distinct gene 
expression profiles (Perou et al. 2000). We were therefore 
not surprised to find that the TNBC subgroup showed a 
distinct gene expression set, among genes pre-selected 
to represent inflammation, ECM remodeling, angiogen-
esis. This signature includes 14 differentially expressed 
genes, four of which were consistently more highly 
expressed (CXCL1, IL1A, IL8, MMP12) and ten genes 
that were repressed in the PABC TNBCs. Of the four 
overexpressed genes, three are linked to inflammation 
(CXCL1, IL1A, IL8), suggesting that TNBCs exhibit a 
more inflammatory phenotype than other subtypes. 
Using Oncomine, we discovered that 11 of the 14 genes 
were previously reported to be associated with the TNBC 
subtype (p value = 0.05, twofold change), with CXCL1 in 
the top 3 % and MMP12 is in the top 1 % of genes associ-
ated with TNBC (Minn et al. 2005; Chin et al. 2006; Tab-
chy et al. 2010). Interestingly, three of the 14 genes (IL1A, 
ELN and TIMP2) to our knowledge have not previously 
been reported to be associated with the TNBC subtype.
CXCL1 was originally reported as a secreted cytokine 
by human melanoma cells and implicated in melanoma 
pathogenesis (Richmond and Thomas 1988). Subsequent 
work implicated CXCL1 in breast, bladder, colon, and 
ovarian cancer (Minn et al. 2005; Yang et al. 2006; Kawan-
ishi et al. 2008; Li et al. 2004). CXCL1 is overexpressed in 
ERα negative breast cancers and high CXCL1 levels are 
correlated with reduced relapse-free survival and metas-
tasis (Bieche et  al. 2007). IL1A is a secreted cytokine 
that promotes inflammatory processes and angiogenesis 
(Matsuo et  al. 2009; Voronov et  al. 2003). IL1A expres-
sion was found to correlate with poor differentiation and 
decreasing ERα expression in breast cancer (Singer et al. 
2003). The expression of the neutrophil chemo-attractant 
inflammatory chemokine IL8 was shown to correlate 
with ERα negativity in breast cancers (Freund et al. 2004) 
and increased metastatic potential of various breast can-
cer cell lines (Bendre et al. 2002).
Of the genes expressed at lower levels in the TNBC 
group, several have been associated with favorable out-
come. The association of TGFB3 mRNA expression with 
breast cancer prognosis and PABC remains somewhat 
elusive, especially since TGFB3 is highly regulated at the 
post-translational level (Flanders and Wakefield 2009). 
However several clinical microarray datasets indicate 
that elevated TGFB3 mRNA is associated with good out-
come and is capable of predicting disease free survival in 
breast cancer (Flanders and Wakefield 2009; van’t Veer 
et  al. 2002; van de Vijver et  al. 2002). Therefore, lower 
levels in our parous TNBC cases are consistent with 
poor prognosis. IHC staining of some selected proteins 
on TMAs showed that there is a reasonable correlation 
between mRNA and protein level for some genes (ER, 
PR, HER2, CDH1), but not others (CXCL1, TGFB3).
In conclusion, in the present study we investigated the 
expression in PABCs of a selected set of genes previously 
demonstrated to differentiate benign breast tissue based 
on parity. We found that the TNBC phenotype occurs 
more frequently among PABCs, and to our knowledge, 
this study is the first to report the elevated prevalence of 
TNBCs and higher grade in PABC as long as 5–10 years 
post-pregnancy. Further, these TNBCs were largely 
responsible for the gene expression differences detected 
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between PABCs and cancers of nulliparous women. Of 
particular interest is our identification of a subset of five 
genes whose expression is similarly altered in both the 
parous normal breast and in the TNBC subset of PABCs. 
The relatively small size of this study, especially the sparse 
number of nulliparous subjects with TNBC, precluded a 
strong statistical test of this hypothesis; thus larger stud-
ies will be required. A survival analysis comparing nul-
liparous patients and PABCs by IHC subtype would also 
be warranted.
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